Bladder Cancer Diagnostics

Bladder cancer has been projected to have the highest lifetime treatment costs per patient of all cancers. Bladder Cancer in the U.S. was estimated to cost $125B in 2010, growing to $155B in 2014. The high recurrence rate and ongoing invasive monitoring requirements drive the financial burden of this disease. Estimates of recurrence of early stage bladder cancer are in the range of 10 to 15% of patients in the first year growing to over half of bladder cancer patients. The current standard of care is cystoscopies with biopsies.
Estimates of the range of false positives based on cystoscopies can range up to 30% driving health care costs up and resulting in patients having to do unnecessary, painful procedures.

OncoCyte is currently developing a diagnostic that could be more effectively used for:

  • Screening for bladder cancer in patients presenting with hematuria
  • Confirming indeterminate cytology findings
  • Diagnosing recurrence of bladder cancer in patients in remission


OncoCyte presented interim clinical study data for the non-invasive detection of bladder cancer at the American Association for Cancer Research (AACR) in April of 2015 demonstrating a high of sensitivity and specificity in the detection of urothelial carcinoma, the most common type of bladder cancer.

Preliminary findings at AACR showed strong performance with a ROC of over 0.9.